Novel 1550-nm Nonablative Resurfacing Laser With Focal Point Technology Improves Fine Lines and Wrinkles With High Energy Delivery
Listen to this summary
The authors aimed to evaluate the effectiveness and safety of a novel 1550-nm nonablative resurfacing laser utilizing Focal Point Technology for improving fine lines and wrinkles across various Fitzpatrick skin types. Their retrospective analysis of 33 subjects demonstrated significant improvement in wrinkle scores and high agreement among blinded reviewers in photographic assessments, indicating that this new laser technology is both safe and effective for treating skin aging.
This is one of 33,000+ journals available on OSLR. Try it free for 14 days.
Free 14-day trial. 33,000+ journals. Cancel anytime.
More from Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
View all →Jun 10, 2026 · Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
Defining the Ideal Cranial Vault Height Ratio Via Morphometric Analysis: A Preliminary Study
Jun 3, 2026 · Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
Lasers and Acquired Melanocytic Nevi: A Systematic Review
More in Dermatology
View all →Aug 6, 2026 · Lancet (London, England)
[<sup>177</sup>Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial
Aug 5, 2026 · The New England journal of medicine
Syncope
Jul 31, 2026 · Lancet (London, England)
Multivessel coronary artery bypass grafting via small thoracotomy versus sternotomy (MIST): an investigator-initiated, international, open-label, randomised controlled trial
Jul 30, 2026 · Lancet (London, England)
Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial
Jul 30, 2026 · Lancet (London, England)
Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial
Jul 29, 2026 · Lancet (London, England)
Deramiocel heart-derived cellular therapy in advanced Duchenne muscular dystrophy (HOPE-3): a phase 3, randomised, double-blind, placebo-controlled trial
"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."
Dr. Jennifer Thompson
Portland, OR
Stay current without falling behind
33,000+ journals. 3-minute audio summaries. Free for 14 days.
